Inhibition of the NLRP3 inflammasome provides neuroprotection in rats following amygdala kindling-induced status epilepticus

Table 1 The development and severity of animals with spontaneous recurrent seizures (SRS) during the 4-week video monitoring in experimental groups

(A) Results from rats after 6 weeks of treatment with NLRP3 siRNA or control siRNA
	The number of rats developing SRS	The time to development of SRS (days)	The mean number of seizures (seizures/day)	The mean seizure duration (sec/seizure)
Control siRNA + sham	0 (18)	0	0	0
NLRP3 siRNA+ sham	0 (18)	0	0	0
Control siRNA + SE	18 (18)	14.8 ± 5.5	7.58 ± 1.09	26.62 ± 6.94
NLRP3 siRNA+ SE	12 (18)^a	27.5 ± 9.3^a	1.34 ± 0.44^a	10.48 ± 2.76^a
(B) Results from rats after 6 weeks of treatment with caspase-1 siRNA or control siRNA
	The number of rats developing SRS	The time to development of SRS (days)	The mean number of seizures (seizures/day)	The mean seizure duration (sec/seizure)
Control siRNA + sham	0 (18)	0	0	0
Caspase-1 siRNA + sham	0 (18)	0	0	0
Control siRNA+ SE	17 (18)	16.6 ± 6.1	9.02 ± 1.56	23.67 ± 5.90
Caspase-1 siRNA+ SE	11 (18)^a	26.8 ± 9.1^a	2.40 ± 0.78^a	8.21 ± 2.66^a

All data are shown as mean ± standard deviation (n = 18 per group). ^a P < 0.05 versus control siRNA treatment.